Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection

Related Articles
Pfizer to partner with Mayo Clinic spinoff on early cardiac amyloidosis detection
Medtech Dive: Anumana, a health technology startup spun out of Mayo Clinic, entered a multi-year agreement with Pfizer to develop an algorithm to detect cardiac amyloidosis, a serious heart condition.…December 16, 2022
How Mayo Clinic is using AI to spot hidden heart conditions
Advisory Board: Mayo Clinic last month released a study suggesting that an artificial intelligence (AI) algorithm could be used to better diagnose a certain heart condition called low ejection fraction—one step…May 31, 2021
Pfizer and Anumana Ink Multi-Year AI Electrocardiogram Algorithm Deal
FDA News: Pfizer has entered into a multi-year deal with Anumana — a joint venture between the Mayo Clinic and nference, an electronic health record data company — to develop…December 20, 2022
Migraine with aura identified as independent risk factor for A-fib
Medical Xpress: Patients with migraine with aura (MwA) have significantly higher artificial intelligence-enabled electrocardiogram (AI-ECG) atrial fibrillation (AF) prediction model output, according to a study from Mayo Clinic published online…August 03, 2022


